Sentence: Numerous phase II and III clinical trials have demonstrated a higher activity of combined gemcitabine plus docetaxel schedules against non-small cell lung cancer ( NSCLC ) than that of both agents in monotherapy .
Drug combination annotation:
[{'class': 'POS', 'spans': ['gemcitabine', 'docetaxel'], 'is_context_needed': False}]